Abstract 4385
Background
For cancer prevention and early diagnostics oncological awareness of the ordinary people is crucial. The knowledge of the problem is extremely important in young population. The aim of the study was to assess the basic oncological knowledge of high school students.
Methods
The study was conducted among high school students in Olsztyn in Poland between April 2017 and April 2018. It was a part of a health promotion program focused on oncological education for high school students in Warmia and Mazury District. The examination was carried out at the beginning of lectures conducted by medical students. The respondents filled in a questionnaire especially prepared for this study. Participation in the study was voluntary and anonymous. The chi-square test was used to compare the subgroups. A p-value <0.05 was considered significant. Statistical analysis was done using STATISTICA software 13.1 (Statsoft, Poland).
Results
The study was done on 227 students (age 17-18 years) from 5 high schools in Olsztyn. There were 125 female and 101 male (one unknown). Almost 80% of responders could correctly defined cancer disease. 153 students (67%) believed genetic predispositions to be the greatest factor affecting cancer morbidity. At the same time, 183 responders (81%) claimed that people have an impact on cancer development. But only 19% students indicated smoking as an important cancerogenous factor and none alcohol. Diet and physical activity influence on cancer prevalence were known only by 5 and 2 students, respectively. Over half of students (58%) thought they lead a healthy lifestyle, but almost 1/3 respondents smoke cigarettes. All students except eight (97%) believed that early detected cancer can be successfully treated. There was no difference depending on sex and place of residence in all questions.
Conclusions
The impact of genetic predispositions in neoplastic diseases seems to be overestimated by high school students. Students knew that lifestyle has an impact on cancer disease, but they did not associate smoking, alcohol, diet, physical activity with a healthy lifestyle. There is a need for more education about cancer and its’ prophylactic among high school students in Poland.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3628 - Predictive model for survival in advanced non-small-cell lung cancer (NSCLC) treated with frontline pembrolizumab
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 3
Resources:
Abstract
5705 - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.
Presenter: Jakob Riedl
Session: Poster Display session 3
Resources:
Abstract
5758 - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab
Presenter: Martin Klabusay
Session: Poster Display session 3
Resources:
Abstract
1743 - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome
Presenter: María Del Mar Noblejas López
Session: Poster Display session 3
Resources:
Abstract
2219 - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy
Presenter: Necdet Üskent
Session: Poster Display session 3
Resources:
Abstract
2996 - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy
Presenter: Carlos Jiménez Cortegana
Session: Poster Display session 3
Resources:
Abstract
2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas
Presenter: Lin Shen
Session: Poster Display session 3
Resources:
Abstract
3515 - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Presenter: Martin Voss
Session: Poster Display session 3
Resources:
Abstract
3566 - Pembrolizumab in Advanced Rare Cancers
Presenter: Aung Naing
Session: Poster Display session 3
Resources:
Abstract
3567 - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Poster Display session 3
Resources:
Abstract